Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Exact Sciences Launches First Stool-Based DNA Screening Test For Colorectal Cancer

Executive Summary

With the cost of treating colon cancer in the US projected to reach $20 billion annually by 2020, Exact Sciences hopes to improve colorectal cancer screening and survival rates with Cologuard, the first FDA-cleared noninvasive screening test that analyzes both DNA and blood biomarkers in stool.

You may also be interested in...



Epigenomics Finally Gains FDA Approval For Epi proColon Blood Test

Epigenomics has finally gained US FDA approval for its Epi proColon noninvasive colorectal cancer screening test, ending what has been a long, obstacle-filled journey for the German-US molecular diagnostics company.

Exact Sciences Colon Cancer Test Gets Quick Results From CMS

CMS granted the company a broad-based national coverage policy at breakneck speed and a positive preliminary payment decision to boot for the Cologuard DNA stool test. It is the first national coverage determination resulting from the FDA-CMS parallel review pilot.

Parallel Review Progress: FDA Approves, CMS Assesses Cologuard Cancer Test

CMS opened a national coverage determination for Exact Sciences Cologuard, the first stool-based colorectal cancer screening test on the same day FDA approved the test. This is the first simultaneous approval/coverage determination under FDA and CMS’ joint parallel review program.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134885

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel